Valuation
- Market cap
- 16,823,000
- Revenue TTM
- $0
- Net income TTM
- $-3,300,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,500
- Avg volume
- 14,694
- Day's range
- $0.06 – $0.08
- Shares out
- 173,792,000
- Stochastic %K
- 39%
- Beta
- -0.67
- Analysts
- —
- Price target
- —
Company profile
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; an...
Show more
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 813 864 2562
- Website
- https://inhibitortx.com
- Address
- 3014 West Palmira Avenue, Suite 302, Tampa, United States
Latest news
No headlines yet.
